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INTRODUCTION
Arthritis, which is a chronic joint disease,
has been known for years as a potentially crippling
disease; but in the main, it has remained of unknown
etiology.

In most cases the treatment is symptomatic

and must be tailored to each individual's needs.
It is for this reason that a complete evaluation is necessary including a history, physical
examination, appropriate laboratory studies, and
roentgenograms.

This affords a knowledge of the

patients's general condition, as 1Nell as any associated or complicating disorders.

The entire patient

must be considered when initiating therapy.
Treatment of arthritis is primarily symptomatic, aimed'at reduction of pain, reduction of
inflammation, adequate rest, and physical therapy.
If pain and inflammation reduction can be maintained,
the rest and physical therapy might naturally follow.
Such local measures as splintage, heat, rest, and
counter-irritation, all play their part in this
reduction of pain and inflammation.
Aspirin has remained the most important drug
in the treatment of arthritis for the past 25 years.
Th.ere are, however, about 25% of arthritis patients

who cannot tolerate aspirin, at least not in analgesic doses.

Intolerance to aspirin is usually

due to gastric irritation or hypersensitivity. (6)
'rfuen aspirin has failed, phenylbutazone compounds, also having both analgesic and antiphlogistic
effects, may be used.

There are many more untoward

effects, however, including salt retention, gastric
irritation, reduction of bleeding time, allergic
rashes, and agranulocytosis.

Phenylbutazone com-

pounds are usually given for a trial period of one
week, if none of the preceding

symp~oms

present with less toxic analgesics.

have been

If, at the

end of one week, improvement is not marked, the
drug is discontinued.(6)
Steroids, primarily prednisone and prednisolone,
may be indicated in severe or difficult arthritis.
They should not be used intermittently or alternated
with aspirin or phenylbutazone, according to Dr.
Kersley.(6)

Side effects of steroids, of course,

include salt retention, hypertension and Cushinoid
appearance.

Steroids are contraindicated in patients

with associated peptic ulcer, severe hypertension,
diabetes mellitus, or recent psychoses.

In cases

such as these, gold therapy may be considered.
(2)

The

effects of gold therapy are less certain and slower
but the benefits are usually longer and side effects
less disturbing.(4)
The majority of this paper will be concerned
with a double-blind clinical evaluation of a new
analgesic agent and its effect on the chronic pain
of arthritis.·· The new drug is known only by the
code name of SQ 10,269.'
CHEMISTT{Y AND PH/\!{lI-Lt\COLCGY

Chemically,

10,269 is 2-Ethoxy-N-methyl-N-

[2-( methylphenethylamino )ethyl] -2, 2-diphenylacetamide
hydrochloride.

The structural formula is as follows:

Hel

10,269 (8, p. 73)

It is classed as a basic amide of diphenylacetic acid.

The parent compound, with similar

4773.

analgesic properties, is
agent,

Sf~

As an analgesic

10,269 is considered to be about 1.5 times

as effective as SQ 4773.

Chemically,

4773 has a

methyl group in place of the phenylethyl group on
the amino nitrogen, as

sho~n

page. (7)
(3)

at top of following

SQ 10,269

SO 4773

SQ 10,269 is a white, odorless, tasteless,
crystalline powder, which dissolves about 1.0% in
water, forming a solution with a pH of 3.5.

It is

very soluble in methanol and chloroform, and is
insoluble in ether. It is stable on exposure to
air, light, and temperatures up to 60°C.(8p.73)
In a series of experiments using mice, SQ 10,269
was found to be about 1.3 times as potent as meperidine and about equal to codeine sulfate and
propoxylene.

Clinically, SQ 10,269 was compared

to codeine sulfate.

The experimental pain thresh-

hold produced by the electrical stimulation of a
metallic filling in a vital tooth was the bas.is for
the comparison.

It was found that 100 mg. of SQ 10,269

had the equivalent analgesic effect of 64 mg. of
codeine and produced a more enduring response.

The

degree of pain relief with SQ 10,269 has been
directly proportional to the dose.

The higher the

dose, however, the higher the incidence of side
effects.

Drowsiness, vertigo, nausea, and vomiting

have been the most prominently reported side effects
(4)

thus far.

No untoward effects on the liver, kidneys,

or hematopoietic system have been noted clinically.
Patients, who have been placed on the drug for as
long as fourteen weeks have shown no evidence of
toxicity or physical dependence.
Vomiting has been noted in dogs with high doses
of SQ 10,269.

All dogs vomited within a few minutes

when in the fasting state and given a dosage of
160 mg./Kg.

However, in the non-fasting state, fifty

per cent of the animals retained doses as large as
320 mg./Kg.

After retained doses of this magnitude,

no effects were observed on the respiratory rate,
blood pressure, heart rate, electrocardiogram, or
pupillary diameter.
The spontaneous motor activity decreased in
mice when given either SQ 10,269 or codeine sulfate.
The decrease was inversely related to the dose.

The

smaller doses caused a greater decrease in activity_
SQ 10,269 tolerance has been demonstrated to
occur at about the same rate as that of meperidine.
Rats developed tolerance to either drug after about
15-20 days.

Tolerance to SQ 10,269 did not show cross

tolerance to meperidine, whereas tolerance to meperidine did show reciprocal tolerance to SQ 10,269.
(5)

Complete withdrawal for 21 days restored the original
effect with either drug.
The median lethal dose (LD50) of SQ 10,269
varied with the concentration of the drug.

The

lower concentrations were more lethal than the
higher concentrations, indicating that the lower
concentrations were more rapidly or completely absorbed from,the

g~strointestinal

tract.

The median

lethal oral dose was estimated to be 325 mg./Kg.
Two of three rats died when given 350 mg./Kg. as a
2% solution,

wher~as

only one of three died when

given 500 mg./Kg. as a 4% solution.

The LD50 of

intravenously administered SQ 10,269 was 40 ± 1.7
mg./Kg.
The effect of chronic ingestion of the drug
was demonstrated by giving three groups of dogs
4.5, 14 and 40 mg./Kg., ,respectfully, for 26 weeks.
All three groups appear,ed alert and healthy throughout the 26 week period.

In the 40 mg./Kg. group,

there were Bromsulfalein changes and an elevation
of the 'Serum Glutamic Pyruvic Transaminase levels
suggestive of depressed liver function.

The inter-

mediate and low dose groups demonstrated no abnormal
laboratory values.

Only the dogs that received 40
(6)

mg./Kg. showed any pathological changes when sacrificed.

In these dogs the liver showed moderate

degeneration evidenced by the following: numerous
homogeneous eosinophilic bodies in liver cells,
a few acidophilic bodies, and an increased number of
double nucleated cells.
SQ 10,269 is considered to be a non-addicting
analgesic agent indicated for the relief of all
types of pain, including post-operative pain and
pain associated with chronic and recurrent diseases.
There are no known contraindications to its use.

At

present the dosage is exploratory, pending the outcome
of further clinical pharmacological trials.

The

dosage originally recommended for this study was
150 mg. four times daily, but was changed to 150 mg.
twice daily.

The change was requested by the manu-

facturer, apparently due to side effects with the
higher dosage.
PURPOSE . 'ND ME:THOD OF STUDY

The purpose of this study was to evaluate the
following:

the extent of pain relief, the presence

and severity of side effects, and the toxicity ,of

SQ 10,269.
The patients selected ,vere moderate to severe
arthritics, and were seen weekly by the author in
(7)

the Arthritis Clinic of the University of Nebraska
College of Medicine.

There were five patients class-

ified with osteoarthritis, seven classified with
rheumatoid arthritis, and one with mixed rheumatoid
and osteoarthritis.

There were two men and eleven

women, and their ages varied from 33 to 84.

Of the

total of thirteen patients selected, eleven completed
the study.

Two patients dropped out due to intol-

erence to the drug.
The medications were supplied as buff colored
gelatin capsules by the Squibb Institute for Medical
Research.

They were labeled only with the codes

of JEX and JEV.

After the study was completed, the

code was broken and revealed that:

JEX was SQ 10,269--150 mg. per capsule
JEV was aspirin----600 mg. per capsule
Each patient served as his own control in
this double-blind study.

The two codes were alter-

nated every week for a total of one month.

The

patients were given a weeks supply of medication and
instructed to take one capsule twice daily with
breakfast and supper.

They were to keep a daily

record of the degree of analgesia, side effects, and
necessary concomitant analgesia.
(8)

No patient was

asked specifically about side effects, and those
recorded were spontaneously expressed by the patient.
At the beginning of the study and at two week
intervals

the study, the following laboratory

dur~ng

values were checked: cOl:nplete blood count, urinalysis, blood urea nitrogen, cephalin cholesterol
flocculation, alkaline phosphatase, and serum glutamic
pyruvic transaminase.
was

discontin~ed.

All prior analgesic medication

All other medications, such as

steroids, gold, cardiovascular and renal medications,
were left unchanged,

At the conclusion of each

patient's test series, the original analgesic medication was again reinstated.
:EVALUATION OF RESULTS

The patient recorded his own daily report on
a form similar to the one reproduced in Fig. 1.
Table 1 is a composite of all the patient report
forms.
Degree of relief
SQ 10,269

Aspirin

o

1

3

7

60

41

42

153

33

41

49

39

0

162

234

Total

Table 1
rfhe code for the degree of relief is as follows:
(9)

Patient's Name

stud;! Week Number

Day of the Week

First

Third

Second

Daily Capsule Number
Pain
Relief
I"".

None
Slight
Moderate
Almost Complete
Complete

I-'

o

'-"

Other Drugs
For
Pain Relief

Name
Amount

Remarks

-.---"-...

--'.--.'-.~-

.. -... ------

~~

-

Fig. 1

Fourth

Fifth

Sixth

Seventh

0,

=

None

3

=

1

=

Slight

4

= Complete

2

= Moderate

Almost complete

The total number of SQ 10,269 observations
should have equaled the total number of aspirin
observations; however, a few of the patients were
unable to complete their entire weekly dosage due to
intolerence of one kind or another.
The effectiveness was compared by using the
method of Cass, Frederik and Bartholomay. (2)

This

was done by employing the following formula:
Number of observations times rating
Total number of observations
The average effectiveness of SQ 10,269 would then
be as follows:
3xO + 7xl + 60x2 + 41x3 + 42x4

=

2.7

153
And the average effectiveness of aspirin would be:
33xO + 41xl + 49x2 + 39x3 + Ox4

=

162

1.6

The means obtained above were compared statistically.

The standard deviation for SQ 10,269

was 0.9975 and that for aspirin was 1.0643.

The

standard error of the difference between the two
(11)

means was 0.115.

This figure divided by the ob-

served difference of 1.1 produced a relative deviate
of 9.5.

This is to say that the possibility of the

difference between the two means being due to chance
alone is a figure 9.5 deviations from the mean.

The

p value then is considerably less than 0.001.(1)
The duration of pain relief with SQ 10,269 was
reported by most patients to be between five and
eight hours.
In compiling the list of side effects, it
should be remembered that these were spontaneous
observations of the patient.
were asked about or suggested.

None of the symptoms
The following table

shows the comparison of side effects elicited in
this study with SQ 10,269 and aspirin.
The most common side effects were vertigo,
drowsiness, and nausea, in that order.

These are

the same side effects mentioned as most prominent
in the literature received from the manufacturer.
The relative incidence, however, appears to be
greater in this study.

No instances of constipa-

tion were reported; but in experimental studies,
SQ 10,269 was shown to be more effective than codeine
in slowing peristalsis.
(12)

SQ 10,269

Side effects
Nausea
Vertigo
Vomiting
Constipation
Drowsiness
Excitement
Headache
Abdominal cramps
Weakness

aspirin

35

1

66
10
0

°0
°07

45

1
7

1
0
0

1

2

Table 2
No significant toxic effects were noted from
the laboratory studies done.

Two patients showed

a' rise from normal in the cephalin flocculation;
however, an equal number returned to normal after
an abnormal control.

The SGPT rose above normal

in one patient on one occasion, and rose above the
control values in several others.

The significance

of these few values is difficult to ascertain, but
the author feels it is small.
Sll1.!MARY

SQ 10,269 is a basic amide derivative of diphenylacetic acid.

It is a new non-narcotic analgesic

which has been evaluated in animal experiments and
is preseptly being studied clinically.

It is an

effective analgesic with a potency equivalent to
that sf codeine.

No toxic effects on hepatic, renal
(13)

or hematopoietic systems have been noted.

While

tolerance has been demonstrated to occur, no indications of addiction have been shown.
This investigative study was conducted in a
double-blind manner using 150 mg. of SQ 10,269 and
600 mg. of aspirin.

The analgesic activity was

compared in thirteen moderately severe arthritis
patients.

Each of the medications had the same

appearance and were alternated w·eekly in each patient
for a total of four weeks.

In this way, each patient

acted as his own control.
The composite results showed that SQ 10,269
was significantly superior to aspirin in the dosages
used.(p 0.001)

The incidence of side effects was

also significantly higher with SQ 10,269.

The

most frequently noted in this and also in previous
studies, have been vertigo, drowsiness, nausea, and
vomiting.

CONCLUSION
In conclusion, SQ 10,269 appears to be an
effective analgesic agent in relieving the pain
due to moderate to severe arthritis.

The side

effects noted, however, might preclude its popularity.
It may be that a smaller single dose at more frequent
(14)

intervals, may be as effective an analgesic without
the incidence of side effects.
ACKNQ1VLEDGEMENTS

Most sincere thanks to Dr. Mary J. Henn for
guidance and assistance throughout this project.
Acknowledgement and thanks to Dr. L. Lizbeth Monroe
and the Squibb Research Institute for their cooperation in supplying the SQ 10,269 and aspirin
preparations.

Also, for the use of their experimental

material in preparing this paper.

Thanks to the

personnel of the Medicine Clinics of the University
of Nebraska College of Medicine for their cooperation.

(15)

BIBLIOGRAPHY
1. Bancroft, Huldah, Introduction to Biostatistics,
Hoeber-Harper Inc., New York, (1957) p. 74
2. Cass, Leo J., Frederik, W. S. and Bartholomay, A. F.
"Methods of Evaluating Ethoheptazine and Ethoheptazine Combined with Aspirin,1t JAMA 166:1829
(1958)

3. Eddy, N. B., "Chemical structure and Action of
Morphine-like Analgesics and Related Substances,"
Chern. and Ind. 47:1462 (1959)
4. Hartfa11, S. J~, "Advances in the Treatment of
Arthritis and Chronic Rheumatism. II Practitioner
183:455 (1959)
5. Hassert, G. L. Jr., Piala, J. J., Burke, J. C.,
and Carver, B. N. "Analgesic ~I\ctivi ty of N-(2dimethylaminoethyl)-2-ethoxy-N-methyl-2,2-diphenylacetamide." Fed. Proc. 20:(1):311 (1961)
6. Kersley, G. D. "Analgesia in Chronic Rheumatic
Conditions." Practitioner 184:58 (1960)
7. Krapcho, J., Turk, C. F.,
gesics. Basic amides of.
acids." Reported to the
Amer. Chern. Soc. N. Y.,

and Lott, W. E. "Anala-alkaxydiphenylacetic
l38Th meeting of the
25 (1960)

8. Squibb, E. R., and sons, Unpublished information
on SQ 10,269 from the Science Information Section
of E. R. Squibb and sons. November 19, 1962
(16)

